Piper Sandler Maintains Overweight on Oscar Health, Lowers Price Target to $45
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and lowers the price target from $48 to $45.
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and lowers the price target from $48 to $45.